1Surveillance, Prevention, and Health Services Research, American Cancer Society, Atlanta, Georgia. *Corresponding Author: Elizabeth J. Schafer, Surveillance ...
Cancer Res (2022) 82 (12_Supplement): 5462.
Abstract. CLDN6 is a membrane-bound oncofetal protein and a promising target for cancers such as ovarian and testicular cancer. AT65474 is an antibody drug conjugate (ADC) candidate composed of a ...
Cancer Res (2024) 84 (6_Supplement): 7536.
The 2025 Nobel Prize in Physics recognizes the discovery of quantum tunneling, now a foundation of quantum computing. That same physics is beginning to reshape cancer research, from drug design and ...
2Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP, Université Paris Cité, Paris, France.
Cancer Res (2019) 79 (13_Supplement): 4484.
1Yonsei University, College of Medicine, Seoul, Republic of Korea.
1Department of Oncology, University of Lausanne, Lausanne, Switzerland.
1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China.
Department of Pharmacology and Toxicology, Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand. *Corresponding Author: John C. Ashton, University of Otago, Frederick Street, ...
1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts. 2Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts. 3Ludwig MIT Center for Molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback